Welcome to our dedicated page for Hoth Therapeutics news (Ticker: HOTH), a resource for investors and traders seeking the latest updates and insights on Hoth Therapeutics stock.
Hoth Therapeutics, Inc. develops clinical-stage therapies for unmet medical needs, with news centered on pipeline progress, regulatory authorizations, intellectual property and financing activity. Company updates frequently cover HT-001, a topical therapeutic for EGFR inhibitor-associated skin toxicities in cancer patients, as well as HT-VA/GDNF metabolic research tied to obesity, MAFLD and related liver-fat pathways.
Other HOTH news themes include patent protection for mast-cell targeting splice-switching oligonucleotide technology, use of the OpenClaw AI-enabled platform for drug-discovery analysis, and capital formation through registered direct offerings and warrant issuances. The company’s public updates generally reflect early-stage pharmaceutical research moving from preclinical work into clinical development.
Hoth Therapeutics (NASDAQ: HOTH) announced deployment of OpenClaw™, an AI-enabled computational platform to accelerate drug discovery across its pipeline.
OpenClaw™ centralizes preclinical and clinical data in real time, standardizes workflows across dermatology, oncology and inflammatory programs, and is designed to speed candidate selection and increase probability of technical success, the company said.
Hoth Therapeutics (NASDAQ: HOTH) reported positive pharmacokinetic, safety, and clinical activity data for topical HT-001 on March 24, 2026. Key PK results: mean AUC₀–₂₄ rose to 80.60 h•ng/mL on Day 42 from 45.61 on Day 1 (~76.7% increase). Mean Cavg increased to 3.36 ng/mL and mean Cmax to 4.56 ng/mL. Accumulation ratios were RA_AUCτ ~2.09x and RA_Cmax ~1.72x. Systemic exposure remained minimal versus oral formulations (~0.2% Day 1, 0.5% Day 42). Safety: no serious adverse events, no dose-limiting toxicities, and no discontinuations due to adverse events. The company linked sustained exposure to observed symptom reductions and supports further development and dose optimization.
Hoth Therapeutics (NASDAQ: HOTH) reported female-specific preclinical data showing its GDNF candidate HT-VA restored serum cholesterol to control-diet levels and maintained lower triglycerides versus semaglutide in western diet–fed female mice. The treatment preserved hepatic autophagy and showed no activation of lipogenesis or pAKT signaling.
Study used female mice (8–10 per group) with eight weeks of diet and four weeks of treatment; results support continued development for MASLD and metabolic dysfunction associated with obesity.
Hoth Therapeutics (NASDAQ: HOTH) deployed the OpenAI API to support IND-enabling development of HT-KIT, its orphan-designated therapy for rare KIT-driven cancers. Key preclinical findings include >80% KIT mRNA/protein suppression, statistically significant tumor-volume reduction by Day 8, and no dose-limiting toxicities reported.
GLP-validated bioanalytical methods are complete and HT-KIT is advancing toward IND submission and Phase 1 clinical evaluation.
Hoth Therapeutics (NASDAQ: HOTH) announced expansion of its CLEER-001 Phase 2a trial with a new enrolling site, Regis Clinical Research in Miami, on Feb 24, 2026.
Interim data show 100% of open-label cohort met the primary ARIGA ≤1 endpoint by week six, 0 dose reductions, >65% meaningful pain/itch relief, and 0 dose-limiting toxicities; the company said the new site will speed enrollment and data collection.
Hoth Therapeutics (NASDAQ: HOTH) received a Notice of Allowance from the USPTO on February 12, 2026, for a patent titled "Exon Skipping of FC-Epsilon-RI-Beta and MS4A6A in the Treatment of Allergic Diseases."
The allowed claims cover a dual-mechanism approach—exon skipping in the high-affinity IgE receptor pathway and modulation of MS4A6A—positioning Hoth to expand its immunology IP, pursue partnerships, and strengthen long-term defensibility in allergic and inflammatory disease markets.
Hoth Therapeutics (NASDAQ: HOTH) reported preclinical VA-backed results showing its HT-VA GDNF outperformed semaglutide in a 12-week CF-1 mouse obesity model. Key findings: female weight attenuation 10–15%, fasting glucose normalized, and liver weight reduced 20–30%. Hoth targets IND-enabling studies toward clinical trials in 2027.
Further analyses (liver pathology, lipids, gene/protein expression) are planned to clarify mechanisms.
Hoth Therapeutics (NASDAQ: HOTH) clarified market rumors about cryptocurrency exposure on February 5, 2026. The company said it holds no cryptocurrency assets and that its maximum exposure over the last year "never reached more than $350,000 USD."
Hoth also reaffirmed ongoing work on the HT-001 clinical trial and progress toward additional oncology and obesity studies.
Hoth Therapeutics (NASDAQ: HOTH) reported positive interim results from the open-label PK cohort of CLEER-001 evaluating HT-001 in cancer patients receiving EGFR inhibitors on Jan 22, 2026. Mean ARIGA scores improved from 1.67 to 0.83 by Week 6 (~50% reduction), with 100% of evaluable patients reaching low-severity disease (ARIGA ≤1). Investigator-assessed CTCAE improved from 2.0 to 1.33 (~34% improvement) and patient-reported pruritus fell from 4.22 to 2.67 (~37% reduction). HT-001 was well tolerated with no unexpected safety signals, supporting the selected dosing and continued development.
Hoth Therapeutics (NASDAQ: HOTH) announced that the China National Intellectual Property Administration approved a key patent for the company's HT-KIT cancer program on January 21, 2026. The patent, originating from a PCT application, covers systems and methods for targeting KIT signaling to induce apoptosis and expands Hoth's intellectual property protection in China, a major oncology market. Hoth said this issuance strengthens its global IP estate for HT-KIT, may enhance future partnering and licensing opportunities, and supports continued development and strategic milestones for the program.